Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 7/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642313 | 0.95 | F2R (0.50) | F2RCNR1TMEM97EPHX2POLB | |
| SCHEMBL641794 | 0.92 | F2R (0.47) | F2RCNR1TMEM97EPHX2POLB | |
| SCHEMBL641909 | 0.90 | F2R (0.54) | F2RCNR1TMEM97EPHX2HRH3 | |
| SCHEMBL641260 | 0.89 | F2R (0.67) | F2RCNR1TMEM97EPHX2POLB | |
| SCHEMBL640578 | 0.88 | F2R (0.45) | F2RCNR1TMEM97HSD11B1MGLL | |
| SCHEMBL3762708 | 0.88 | F2R (0.49) | F2RCNR1TMEM97EPHX2POLB | |
| SCHEMBL642020 | 0.88 | F2R (0.53) | F2RCNR1TMEM97EPHX2 | |
| SCHEMBL641532 | 0.88 | F2R (0.67) | F2RPOLB | |
| SCHEMBL641521 | 0.85 | F2R (0.47) | F2RCNR1TMEM97EPHX2MGLL | |
| SCHEMBL642085 | 0.85 | F2R (0.51) | F2RCNR1TMEM97EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120129831-A1 | Substituted 3-(1,2,4-Oxadiazol-5-yl)-5-Phenylpiperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129831-A1 | Substituted 3-(1,2,4-Oxadiazol-5-yl)-5-Phenylpiperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129831-A1 | Substituted 3-(1,2,4-Oxadiazol-5-yl)-5-Phenylpiperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2227466-B1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AG (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2227466-B1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AG (DE) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010136127-A1 | SUBSTITUTED 3-(1,2,4-OXADIAZOL-5-YL)-5-PHENYLPIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136127-A1 | SUBSTITUTED 3-(1,2,4-OXADIAZOL-5-YL)-5-PHENYLPIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| EP-2227466-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | F2R 698/4885CNR1 454/4885TMEM97 1110/4885 |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | F2R 698/4885CNR1 454/4885TMEM97 1110/4885 |
| US-20120129831-A1 | Substituted 3-(1,2,4-Oxadiazol-5-yl)-5-Phenylpiperidines | VHL, TNNI3, PTGIS | F2R 1675/4885CNR1 611/4885TMEM97 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.